Skip to main content
Fig. 2 | Journal of Experimental & Clinical Cancer Research

Fig. 2

From: VEGF-A/VEGFR-1 signalling and chemotherapy-induced neuropathic pain: therapeutic potential of a novel anti-VEGFR-1 monoclonal antibody

Fig. 2

VEGF-A family members induce hypersensitivity through interaction with VEGFR-1. The response to a thermal stimulus (Cold plate test) was recorded after i.t. infusion of different VEGFR ligands (30 ng) preceded (15 min before) or not by the anti-VEGFR-1 mAb D16F7 (100 ng) or vehicle: (a) VEGF165b ± D16F7 (n = 5), (b) PlGF-2 ± D16F7 (n = 5), (c) VEGF-E ± D16F7 (n = 5). (d) Representative western blot images and densitometric analysis showing the expression of VEGFR-1 or VEGFR-2 in the lumbar section of the spinal cord after the siRNAs administration (n = 5). (e - f) Effects of VEGFR ligands (i.t.) in mice undergone a selective knockdown of VEGFR-1 (e, n = 5) or VEGFR-2 (f, n = 5) at the lumbar level of the spinal cord by siRNA. Each value represents the mean ± SEM. **P < 0.01 vs vehicle + vehicle-treated animals; °°P < 0.01 vs vehicle + VEGFRs ligands-treated animals. The analysis of variance was performed by one-way ANOVA. A Bonferroni’s significant difference procedure was used as post-hoc comparison

Back to article page